HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER
Rhea-AI Summary
Haleon (NYSE: HLN) has appointed Carl Haney as Chief Research & Development Officer, effective August 1, 2025. Haney joins from Estée Lauder Companies Inc., where he served as Executive Vice President of Global Innovation and R&D for 13 years, following a 20-year tenure at P&G.
Haney succeeds Franck Riot, who is departing after six years with the company. CEO Brian McNamara highlighted Haney's expertise in driving transformative innovation within global consumer businesses, emphasizing his role in implementing Haleon's new Win as One strategy.
Positive
- Appointment of experienced R&D executive with over 33 years of experience in global consumer businesses
- Strategic alignment with company's Win as One strategy and transformation goals
- Strengthening of executive leadership team with expertise in transformative innovation
Negative
- Departure of current R&D Officer Franck Riot after 6 years indicates potential disruption in R&D leadership continuity
News Market Reaction
On the day this news was published, HLN declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
This appointment follows Franck Riot deciding to leave Haleon after six years in the business.
Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care.
Brian McNamara, Haleon's Chief Executive Officer commented:
"I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experience of driving transformative innovation within global consumer businesses. He will be an excellent addition to our executive team as we look to build on the strong foundations we have built in recent years and unlock Haleon's significant potential through our new Win as One strategy.
"I want to take this opportunity to thank Franck for his significant contribution to Haleon over the last six years. He has played an important role in the lead up to and beyond separation to move our innovation agenda forward and prepare us for the next phase of our journey. On behalf of everyone at Haleon, I wish him the very best for the future."
Carl Haney commented:
"I am hugely excited to be joining Haleon at such an important stage of its journey, as it looks to capitalise on the significant opportunities ahead and continues its transformation into a world class consumer company. I am incredibly passionate about the role that R&D can play in delivering Haleon's ambitions and its purpose of delivering better everyday health with humanity. I am very much looking forward to meeting the team and getting started in August."
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
Photo - https://mma.prnewswire.com/media/2717039/Haleon.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/haleon-appoints-carl-haney-as-chief-rd-officer-302488742.html
SOURCE Haleon
FAQ
Who is the new Chief R&D Officer at Haleon (NYSE: HLN)?
What is Carl Haney's previous experience before joining Haleon?
Who did Carl Haney replace as Haleon's R&D Officer?
When will Carl Haney start his role at Haleon (HLN)?
What is Haleon's new strategy mentioned in the announcement?
